These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 24127691

  • 21. Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.
    Gonvers JJ, Heim MH, Cavassini M, Müllhaupt B, Genné D, Bernasconi E, Borovicka J, Cerny A, Chave JP, Chuard C, Dufour F, Dutoit V, Malinverni R, Monnat M, Negro F, Troilliet N, Oneta C.
    Swiss Med Wkly; 2010; 140():w13055. PubMed ID: 20648398
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
    Shea DO, Tuite H, Farrell G, Codd M, Mulcahy F, Norris S, Bergin C.
    J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
    Payan C, Pivert A, Morand P, Fafi-Kremer S, Carrat F, Pol S, Cacoub P, Perronne C, Lunel F, ANRS HC02 RIBAVIC study team.
    Gut; 2007 Aug; 56(8):1111-6. PubMed ID: 17363475
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
    Nicot F, Alric L, Barange K, Métivier S, Dramard JM, Combis JM, Castan B, Meurisse JJ, Payen JL, Garipuy D, Desmorat H, Peron JM, Thebault S, Morin T, Renou C, Barel P, Guerin B, Imbert Y, Sire S, Sauné K, Chatelut E, Izopet J.
    J Med Virol; 2011 Mar; 83(3):437-44. PubMed ID: 21264864
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy.
    Guzmán-Fulgencio M, Berenguer J, Rallón N, Fernández-Rodríguez A, Miralles P, Soriano V, Jiménez-Sousa MA, Cosín J, Medrano J, García-Álvarez M, López JC, Benito JM, Resino S.
    AIDS; 2013 May 15; 27(8):1231-8. PubMed ID: 23811951
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M, Von Wichmann MA, Van den Eynde E, Navarro J, Cifuentes C, Murillas J, Veloso S, Martínez-Rebollar M, Guardiola JM, Jou A, Gómez-Sirvent JL, Cervantes M, Pineda JA, López-Calvo S, Carrero A, Montes ML, Deig E, Tapiz A, Ruiz-Mesa JD, Cruceta A, de Lazzari E, Mallolas J.
    Int J Infect Dis; 2016 Dec 15; 53():46-51. PubMed ID: 27815225
    [Abstract] [Full Text] [Related]

  • 35. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Martín-Carbonero L, Puoti M, García-Samaniego J, De Luca A, Losada E, Quinzan G, Bruno R, Mariño A, González M, Núñez M, Soriano V.
    J Viral Hepat; 2008 Oct 15; 15(10):710-5. PubMed ID: 18637070
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, Massetto B, Gaggar A, Ni L, Svarovskaia E, Brainard D, Subramanian GM, McHutchison JG, Puoti M, Rockstroh JK, PHOTON-2 study team.
    Lancet; 2015 Mar 21; 385(9973):1098-106. PubMed ID: 25659285
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.